Clavis and Clovis Sign Licensing Deal for Cancer Drug
Start-up biotech Clovis Oncology has signed a $380 million deal to license an experimental pancreatic cancer drug from Norwegian company Clavis Pharma.
Month: November 2009
Cancer Vaccines: Investing Opportunities Beyond Dendreon
Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space, recent advancements and study results are encouraging.
[Company Profile] Ivivi Technologies
This targeted, a priori designed, micro-current is designed to enhance and accelerate the body’s natural healing processes to help repair injured tissue and to reduce related pain and inflammation.
Join Us at the 3rd Annual OneMedPlace Finance Forum
Over 100 companies and 500 investors are expected to attend the OneMedPlace Finance Forum, to take place from January 12-14 in San Francisco.
CytRx to Initiate Clinical Trial for Soft Tissue Cancer Drug
CytRx, a biopharmaceutical research and development company, has announced plans to initiate a Phase II clinical trial for its drug candidate INNO-206 to treat patients who suffer from advanced, treatment-resistant soft tissue sarcoma.
ImmunoGen Signs 2nd Licensing Deal with Amgen
ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million.
[Company Profile] Pico-Tesla Magnetic Therapies
Pico-Tesla Magnetic Therapies, an emerging medical technology company based in Littleton, CO, has commenced a pilot study of its Magneceutical™ Therapy as a treatment for type 2 diabetes, the most common form of the disease.
Echo Therapeutics: Positive Developments for Needle-Free Monitoring System
On 11/19/09, the Company announced positive results in a pilot clinical study which included Prelude skin preparation and the placement of 10 Symphony tCGM biosensors on subjects with Type 1 or Type 2 Diabetes.
Controversy Over New Breast Cancer Screening Guidelines
The U.S. Preventive Services Task Force recommended this week that women should begin getting routine mammograms at the age of 50 instead of the previously recommended age of 40.
Spherix Shares Rise on Promising Diabetes Drug Data
Shares in Spherix shot up by 77 percent after the biotechnology company announced preliminary Phase III results for its Type 2 diabetes drug candidate.